Key facts
- Vitarka Therapeutics’s last known valuation is $900K (Apr 2022).
- It has raised $1.7M; the latest was Seed Round in Dec 2024.
- Notable investors include Innovate UK, SOSV, IndieBio, Future Planet Capital, UK Innovation & Science Seed Fund — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vitarka Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vitarka Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vitarka Therapeutics
Developer of a targeted non-viral delivery platform designed for intracellular targets in neuroscience and neurodegeneration. The company's platform activates the immune system and normalizes the tumor vasculature to significantly change outcomes for late-stage patients with lung, colon, breast, and other cancers, cell-specific targeting, and endosomal release of cargo, enabling cancer patients to get a chance to lead a normal life and be hopeful for the future.
- Sector
- Healthcare
- HQ
- Sandwich, United Kingdom
- Founded
- 2021
- Employees
- 6
- Website
- vitarka.co.uk/
- Ownership
- Privately Held (backing)
Vitarka Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vitarka Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vitarka Therapeutics in its N-PORT filings yet. We sweep new filings monthly.